This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1243 entries already.
GEA has launched its second Food Application and Technology Center (ATC) globally in the US, to target the largest consumer market for cellular agriculture. The facility features advanced bioreactors and precision fermentation systems that enable companies to test and optimise processes for producing alternative proteins and other novel food products.
Lose weight without expensive obesity pills? The discovery of a direct link between olfactory receptors and areas of the brain that signal satiety makes this seem possible, initially in mice.
SpliceBio SL has baged US$135m in a Series B financing co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors The Barcelona-based company will use the proceeds to advance SB-007 in Stargardt disease and expand its pipeline of meds that regulate splicing.
Obstructive sleep apnea (OSA) specialist Mosanna Therapeutics AG has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118.
The Spanish BIO-CAT cluster has launched a new accelerator called ATMP Catalyst, which will support six preclinical gene and cell therapy projects per year in each of three annual calls to support translation into clinical development.
Belgian micriobial fermentation specialist AmphiStar NV has partnered with US plant-based ingredient heavyweight Kensing to market its biosurfactants in the US, using locally-produced feedstocks. Amphistar’s biosurfactants are an alternative to palm oil made surfactants that are 25% of the current US$20bn surfactant market.
Pharmaceutical associations have responded with sharp criticism to the adoption of the revised general pharmaceutical legislation by the EU Council of Ministers in the form of a directive and a regulation. They argue that the measures are not suitable for bringing Europe back to the forefront of pharmaceutical research and will make the EU an unattractive location for investment.
In the race to replace MSD’s mega blockbuster pembrolizumab with a more effective bispecific VEGF x PD-(L)1 antibody, German company BioNTech SE has struck a good deal. BioNTech is now developing its Phase III programme BNT327, acquired with the US$950m takeover of Chinese company Biotheus Co Ltd, with Bristol Myers Squibb (BMS) in return for a payment of US$11.1bn.
Scotland’s biotechnology sector is celebrating a major milestone with the launch of the nation’s first open-access 300-litre fermenter – a state-of-the-art piece of equipment that will support early-stage companies to develop bio-based products at scale.
German researchers have identified a promising new target to stop the inflammatory response in ulcerative colitis—a breakthrough that could help prevent the progression to colorectal cancer. Phase II clinical trials of a corresponding monoclonal antibody, licensed by Roche, are expected to begin soon.